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We investigated whether an increase in enterococcal bloodstream 
infections (BSIs) depends on the emergence of Enterococcus faeciutn 
in an area with low vancomycin-resistant enterococci prevalence. 
From 1999 to 2012, a linear increase in E. faecium BSI rates (0.009 
per 1,000 patient-days per year; f<.001) was noted. Enterococcus 
faecalis BSI rates remained stable. 
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In recent decades, enterococci have evolved from harmless 
intestinal commensals to important nosocomial pathogens 
worldwide.1 In US hospitals during the 1980s, a shift from 
ampicillin-sensitive Enterococcus faecalis to ampicillin-resis-
tant Enterococcus faecium (AREfm) was noted. Nowadays, 
vancomycin-resistant enterococci (VRE) account for more 
than 25% of enterococcal bloodstream infections (BSIs).2 In 
Europe, however, AREfm and vancomycin-resistant E. fae-
cium (VREfm) have been observed in clinical isolates only 
since 2000,3 with large differences in the prevalence of VRE. 
In Switzerland, very low VRE rates are reported (less than 
5%).4 The emergence of AREfm without an increasing in-
cidence of VREfm of the VanA/B type in our institution al-
lowed us to test the hypothesis that AREfm is primarily re-
sponsible for the overall increase in enterococcal infections. 
M E T H O D S 
We retrospectively analyzed all routine blood cultures with 
growth of enterococci from patients hospitalized at the Uni-
versity Hospital Basel (UHBS), Switzerland, an 800-bed ter-
tiary care teaching hospital, from January 1999 to December 
2012. Data were extracted from the microbiological database 
and cross-checked by analysis of an independent backup sys-
tem from the microbiology laboratory mainframe computer 
(ML Query DORNER EDV Systeme, Mephisto DB, HyBase). 
From medical charts, all patients with enterococcal bac-
teremia were evaluated for the presence of a BSI. Two of the 
following criteria qualified for BSI: temperature more than 
38°C or less than 36°C, heart rate more than 90 per minute, 
tachypnea more than 20 per minute, and leukocytes either 
more than 12 x 109/L or less than 4 x 109/L (or more than 
10% immature neutrophils). Nosocomial BSI was defined as 
BSI occurring more than 48 hours after hospital admission. 
Only the first enterococcal BSI per patient per year was in-
cluded. BSI rates were calculated with respect to species dif-
ferentiation (E. faecalis, E. faecium, other enterococci, Entero-
coccus spp.) expressed per 1,000 patient-days. The study was 
approved by the local ethical committee (EKBB 208/09). 
Enterococcal species identification was performed by Vitek 
2 (bioMerieux). Susceptibility testing was done for the first 
positive isolate of a patient's BSI. Minimal inhibitory con-
centrations (MICs) for ampicillin, ciprofloxacin, and van-
comycin were performed by a semiautomated microdilution 
assay system (Micronaut; Merlin). Susceptibility to high-level 
gentamicin was tested using the Etest (AB Biodisk; later 
bioMerieux). MICs were interpreted according Clinical and 
Laboratory Standards Institute guidelines until 2011 and ac-
cording to European Committee on Antimicrobial Suscep-
tibility Testing thereafter. From February to October 2008, 
20 consecutive E. faecium blood isolates were typed with mul-
tilocus sequence typing (MLST) and multiple locus variable 
number tandem repeat analysis (MLVA), as described 
elsewhere.5'6 
For comparison of the changes in infection rates, a linear 
regression model was used. A P value of less than .05 was 
considered to indicate statistical significance. 
RESULTS 
During the study period, of 22,518 positive blood cultures, 
1,179 (5.2%) from 453 patients grew enterococci. Of these, 
424 originated from hospitalized patients, and 404 had a BSI. 
Species identification revealed 160 E. faecium (39.6%), 215 
E. faecalis (53.2%), 18 other enterococci (4.5%), and 22 non-
specified isolates (5.4%). In 11 patients, two different entero-
coccal species were present simultaneously. 
Over the study period, a linear increase in the rate of en-
terococcal BSI of 0.01 per 1,000 patient-days per year was 
observed (P<.001; Figure 1). For E. faecium, the increase 
was 0.009 per 1,000 patient-days per year {P < .001), manifest 
mostly after 2004. For E. faecalis, the rate was stable over 
time (median, 0.064 per 1,000 patient-days; range, 0.031-
0.091; P = .153). Overall, 267 (66%) BSIs were nosocomial. 
Whereas the rate of nosocomial E. faecium BSI increased over 
the study period, the rates of community-acquired E. faecium 
BSI and of nosocomial and community-acquired E. faecalis 
BSI remained stable. Most patients with a nosocomial E. fae-
cium BSI were hospitalized in the intensive care unit or the 
hematology ward. On the hematology ward, the contribution 
of E. faecium BSI increased from 0% before 2004 to 22% of 
BSIs with any pathogen in 2012 (data not shown). 
During the study period, only 1 BSI with a VRE VanB was 
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FIGURE i. Bloodstream infections (BSIs) with enterococci (cases per 1,000 patient-days). Bars indicate BSIs with different enterococcal 
species per 1,000 patient-days during the period 1999-2012. Other enterococci consisted of E. casseliflavus (« = 8), E. durans (n = 3), 
E. avium (n = 3), E. gallinarum (n = 3), and E. hirae (n = 1). Lines indicate E. feacium BSIs per 1,000 patient-days during the period 
1999-2012 according to nosocomial and community-acquired origin. 
noted, in 2002. Among E. faecium isolates, ampicillin resis-
tance rose from 0% in 1999 to 100% in 2012 in 1 and 14 
tested isolates, respectively, with important fluctuations over 
time, mainly due to small numbers (Figure 2). The frequency 
of resistance to high-level gentamicin increased from 0% to 
58%. Resistance of E. faecium to quinolones increased slightly. 
E. faecalis isolates remained constantly susceptible to ampi-
cillin and vancomycin and showed low rates of resistance to 
ciprofloxacin and high-level gentamicin. 
MLST of 20 consecutive AREfm BSI isolates revealed 15 
isolates with sequence type (ST) 78, 1 with ST192, and 1 with 
ST168, all corresponding to MT159 in MLVA. One isolate 
with ST168 corresponded to MT39. In 2 isolates (ST94 and 
ST22), no full MLVA profile was obtained, and no MT could 
be assigned. Resistance to ampicillin was present in 19 of 
these 20 isolates. 
DISCUSSION 
The increase in E. faecium BSIs over the 14-year period doc-
umented in our study reflects the change in global entero-
coccal epidemiology as described in other studies.3 In contrast 
to what has been thought previously, in our study E. faecium 
did not replace E. faecalis but was introduced newly into the 
nosocomial setting, similar to the emergence of methicillin-
resistant Staphylococcus aureus, which occurred on top of 
methicillin-susceptible S. aureus.7 This has also recently been 
shown for other nosocomial pathogens.8 
The typing results of our study, although performed only 
during a short time period, document the presence of a 
known hospital-adapted epidemic clone. MLST ST78 belongs 
to the so-called clonal complex 17, after the presumed foun-
der ST 17. These clones—observed in many hospitals world-
wide irrespective of the presence of VRE—are characterized 
by acquisition of multiple virulence and resistance genes.9 
Whether they originate from cross-transmission in the hos-
pital environment or whether preexisting AREfm outgrow the 
microbiome under strong selection pressure (eg, antibiotics) 
has not been proven yet, and it might be a multifaceted 
process, but data suggest transmission of a limited number 
of highly related AREfm clones within wards.3 
Our study confirms reported resistance rates from the Swiss 
Center for Antibiotic Resistance (anresis). For the year 2011, 
published resistance rates for nosocomial E. faecium isolates 
were 86% for ampicillin (n — 1,680), 37% for high-level gen-
tamicin (n = 481), and 3% for vancomycin (n — 1,151).4 
Despite the low prevalence of VRE, the possibility of inte-
gration of vanA and vanB into a suitable "genetic back-
ground" is a major concern. The first outbreak of 31 VREfm 
was reported in 2011 in western Switzerland.10 
Whether strict infection control measures, as recom-
mended for MRSA or VRE, are effective and feasible for 
AREfm remains a matter of debate. Enterococci persist in 
patient environments for long time periods and are notori-
ously difficult to eradicate.3 Intensified infection control 
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FIGURE 2. Resistance in Enterococcus faecium and Enterococcus faecalis from blood isolates. Lines show the percentage of resistant isolates 
(resistant isolates/tested isolates) among all E. faecium and E. faecalis isolates for the different antibiotics over time. HL, high level. 
might be useful during a hospital outbreak. Its usefulness in 
a slowly changing epidemiology is unclear. 
The strength of our study lies in the long observation pe-
riod with data available on clinically relevant BSI. A limitation 
is the single-center study design, which makes extrapolation 
to other institutions difficult. Furthermore, typing data are 
limited to a short time period of the whole study, so it is 
possible that outbreaks with different types were missed. 
In conclusion, we confirmed the emergence and gradual 
increase of an epidemic nosocomial E. faecium clone in BSI 
on top of a stable rate of infections with E. faecalis and com-
munity-acquired E. faecium. The nosocomial E. faecium 
clones belonging to CC17 might be the basis for the emer-
gence of VRE. 
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